1.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a random...
by Sax, Paul E, Dr
The Lancet (British edition), 2012, Vol.379 (9835), p.2439-2448
2.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
3.
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofo...
by Pozniak, Anton, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.590-599
4.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
by Madruga, José Valdez, Dr
The Lancet (British edition), 2007, Vol.370 (9581), p.29-38
5.
Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents
by Matteau, Alexis, MD, MSc
The American journal of cardiology, 2015, Vol.116 (5), p.686-693
6.
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
by Fleischer, David M., MD
Journal of allergy and clinical immunology, 2015, Vol.136 (2), p.258-261
7.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-cont...
by Mills, Anthony, MD
The Lancet infectious diseases, 2016, Vol.16 (1), p.43-52
8.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two m...
by Eron, Joseph J, Prof
The Lancet (British edition), 2010, Vol.375 (9712), p.396-407
9.
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
by Eron, Joseph J, Prof
The Lancet infectious diseases, 2011, Vol.11 (12), p.907-915
10.
The association between physician risk tolerance and imaging use in abdominal pain
by Pines, Jesse M., MD, MBA, MSCE
The American journal of emergency medicine, 2009, Vol.27 (5), p.552-557
11.
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
by Becker, Richard C, Prof
The Lancet (British edition), 2009, Vol.373 (9667), p.919-928
12.
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
by Fleischer, David M
Journal of allergy and clinical immunology, 2015, Vol.136 (2), p.258
13.
Derivation of a clinical prediction rule for evaluating patients with abdominal pain and diarrhea
by Chen, Esther H., MD
The American journal of emergency medicine, 2008, Vol.26 (4), p.450-453
14.
Emergency Ultrasound Usage Among Recent Emergency Medicine Residency Graduates of a Convenience Sample of 14 Residencies
by Dean, Anthony J., MD
The Journal of emergency medicine, 2010, Vol.38 (2), p.214-221
